Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Facial Injectables Market is expected to reach USD 17.2 billion by 2025

Reportlinker
Posted on: 20 Jun 17
Facial Injectables Market is expected to reach USD 17.2 billion by 2025

PR Newswire

NEW YORK, June 19, 2017

NEW YORK, June 19, 2017 /PRNewswire/ -- Highlights

  • All these factors are expected to assist in the market growth over the forecast period.
  • Minimally invasive surgery, an advanced medical technology, is used for facial rejuvenation, endoscopy, laparoscopy, arthroscopy and other procedures.
  • This procedure is gaining popularity over time owing to faster recovery, low instances of postsurgery infections, lower pain, reduced scarring, and high accuracy & maximum benefits.


The global facial injectables market is expected to reach USD 17.2 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to exhibit lucrative growth during the forecast period, owing to advancements in facial rejuvenation procedures and increasing importance of medical aesthetics across the globe.


Development in products & procedures, as well as change in patient demographics is helping dermatologists and physicians treat multiple facial areas. These advancements help dermatologists or physicians develop customized treatment for patients and facilitate use of combination products to obtain better outcomes. All these factors are expected to assist in the market growth over the forecast period. Augmented products such as Botulinum Toxin Type A (BoNTA) and Hyaluronic Acid (HA) fillers are used in combination to improve outcomes, especially in the lower face procedures. HA fillers are mostly preferred by physicians due to their better acceptance (few instances of hypersensitivity reactions), biodegradable nature, & high viscosity as well as for the longevity they provide to the restored volume.

Minimally invasive surgery, an advanced medical technology, is used for facial rejuvenation, endoscopy, laparoscopy, arthroscopy and other procedures. This procedure is gaining popularity over time owing to faster recovery, low instances of postsurgery infections, lower pain, reduced scarring, and high accuracy & maximum benefits. For instance, as per International Society of Aesthetic Plastic Surgery (ISAPS), more than 20.0 million surgical and nonsurgical cosmetic procedures were performed worldwide in 2014.The number of HA-based surgeries performed in 2014 was 2,690,633, which increased to 2,865,086 in 2015, which is thereby expected to contribute to the growth of this space over the forecast period.


Further key findings from the study suggest:
• The hyaluronic acid segment held a lucrative share in 2016 and is expected to grow at a significant rate over the forecast period owing to increasing preference for combination treatments such as hyaluronic acid with BoNTA.
• The BoNTA segment is anticipated to witness the fastest growth over the forecast period due to increasing application in aesthetics and therapeutics
• The aesthetics segment is expected to dominate the market during the forecast period owing to increasing expenditure on aesthetic procedures coupled with rising beauty consciousness among consumers
• North America is expected to dominate the facial injectables market over the forecast period due to growing geriatric population base, increasing consumer disposable income, and surge in number of facial procedures in the region
• Some of the key players in facial injectables market are ALLERGAN; Ipsen; Merz Pharma; Suneva Medical, Inc.; Medytox, Inc.; Sinclair Pharma; Bloomage BioTechnology Corporation Limited; Anika Therapeutics, Inc.; Prollenium Medical Technologies Inc.; and Galderma S.A.
Read the full report: http://www.reportlinker.com/p04946483/Facial-Injectables-Market-Analysis-By-Product-Collagen-Hyaluronic-Acid-Botulinum-Toxin-Type-A-Calcium-Hydroxylapatite-Polymer-Fillers-By-Application-Aesthetics-Therapeutics-By-Region-And-Segment-Forecasts.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com


__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/facial-injectables-market-is-expected-to-reach-usd-172-billion-by-2025-300476337.html

SOURCE Reportlinker

PR Newswire
www.prnewswire.com

Last updated on: 20/06/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.